The Development of a Precision Medicine Platform to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma

被引：0
|
作者：
Liu, Yang [1 ]
Zhao, Shuangtao [2 ]
Jiang, Changying [1 ]
Yao, Yixin [1 ]
Murfin, Kelley Paige [1 ]
Grundman, Hadley [1 ]
Zhang, Liang [1 ]
Nomie, Krystle [1 ]
Wang, Linghua [2 ]
Wang, Michael [1 ,3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-131079
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1487
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma
    Zhao, Xiaohong
    Wang, Michelle Y.
    Jiang, Huijuan
    Lwin, Tint
    Park, Paul M.
    Gao, Jing
    Meads, Mark B.
    Ren, Yuan
    Li, Tao
    Sun, Jiao
    Fahmi, Naima Ahmed
    Singh, Satishkumar
    Sehgal, Lalit
    Wang, Xuefeng
    Silva, Ariosto S.
    Sotomayor, Eduardo M.
    Shain, Kenneth H.
    Cleveland, John L.
    Wang, Michael
    Zhang, Wei
    Qi, Jun
    Shah, Bijal D.
    Tao, Jianguo
    CELL REPORTS, 2021, 34 (11):
  • [22] HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma
    Jacobson, Caron
    Kopp, Nadja
    Layer, Jacob V.
    Redd, Robert A.
    Tschuri, Sebastian
    Haebe, Sarah
    van Bodegom, Diederik
    Bird, Liat
    Christie, Amanda L.
    Christodoulou, Alexandra
    Saur, Amy
    Tivey, Trevor
    Zapf, Stefanie
    Bararia, Deepak
    Zimber-Strobl, Ursula
    Rodig, Scott J.
    Weigert, Oliver
    Weinstock, David M.
    BLOOD, 2016, 128 (21) : 2517 - 2526
  • [23] Mantle cell lymphoma of the iris treated by ibrutinib
    De Gauzy, T. Sales
    Oberic, L.
    Fournie, P.
    Soler, V.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2018, 41 (10): : E501 - E502
  • [24] Oncogenic MALT1 Promotes Cell Survival and Mediates Ibrutinib Resistance and Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma
    Jiang, Vivian Changying
    Lian, Junwei
    Huang, Shengjian
    Zhang, Shaojun
    Liu, Yang
    Wang, Linghua
    Wang, Michael
    BLOOD, 2020, 136
  • [25] Mechanism of action of Ibrutinib in mantle cell lymphoma
    Sun, Zhijian
    Zhou, Dongping
    Wei, Min
    Luo, Lusong
    CANCER RESEARCH, 2014, 74 (19)
  • [26] Molecular Profiling plus In Vitro and In Vivo Drug Efficacy Analyses Identifies Novel Treatments to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
    Liu, Yang
    Nomie, Krystle
    Jiang, Changying
    Yao, Yixin
    Zhang, Liang
    Wang, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S318 - S318
  • [27] Interrogation of Dysregulated Pathways Enables Precision Medicine in Mantle Cell Lymphoma
    Liu, Yang
    Zhao, Shuangtao
    Jiang, Changying Changying
    Yao, Yixin
    McIntosh, Joseph
    Jordan, Alexa A.
    Li, Yijing
    Che, Yuxuan
    Jain, Preetesh
    Wang, Linghua
    Wang, Michael
    BLOOD, 2020, 136
  • [28] Using the Iron Chelator Deferasirox to Overcome Drug Resistance in Mantle Cell Lymphoma
    Samara, Aladin
    Shapira, Saar
    Lubin, Ido
    Raanani, Pia
    Granot, Galit
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S408 - S409
  • [29] Using the Iron Chelator Deferasirox to Overcome Venetoclax Resistance in Mantle Cell Lymphoma
    Halperin, Erez
    Shapira, Saar
    Samara, Ala Aladin
    Raanani, Pia
    Granot, Galit
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S514 - S514
  • [30] Using the Iron Chelator Deferasirox to Overcome Drug Resistance in Mantle Cell Lymphoma
    Samara, Aladin
    Shapira, Saar
    Lubin, Ido
    Raanani, Pia
    Granot, Galit
    BLOOD, 2021, 138
12345